reptides › growth hormone › ghrp-2

ghrp-2

first-gen GH releaser. works. also spikes cortisol, prolactin, and hunger. ipamorelin replaced it.

tier D · growth hormone · PMDA '04 Japan diagnostic

verdict

first-gen GH releaser. works. also spikes cortisol, prolactin, and hunger. ipamorelin replaced it.

if you're asking GHRP-2 vs ipamorelin — ipamorelin binds the same receptor, produces the same pulsatile GH release, and carries a cleaner endocrine profile. no measurable change in cortisol, prolactin, or ACTH at clinically relevant doses. GHRP-2's cortisol and prolactin elevation are well-established (Arvat 2001, Laferrere 2005). the remaining GHRP-2 use case is appetite stimulation, not a superior GH signal.

if you're asking about the diagnostic / clinical anchor — GHRP-2 is used as a diagnostic provocation test for GH deficiency. that's a legitimate clinical anchor newer research peptides don't have. the GH pulse is real, robust, and well-characterized. that's the part of the compound that holds up. the rest is what makes most modern GH-axis protocols skip it in favor of ipamorelin.

if you came in for the appetite-stimulation effect — this is the surviving case. for users who want appetite stimulation during a bulk, the hunger spike is a feature rather than a bug. it's cheap, available, and pharmacologically real. that's a different use case from chronic GH-axis optimization, where the cortisol and prolactin elevation makes it the wrong choice.

based on published evidence and disclosed clinical practice. not medical advice.

why D-tier

D-tier because a cleaner alternative, ipamorelin, exists with the same core receptor target and less cortisol/prolactin baggage. Not F-tier because GHRP-2 works, it is a legitimate compound with a real mechanism and real effects, just worse than its direct successor for most GH-axis use cases. This is obsolete tier, not broken tier. With ipamorelin available as the cleaner comparator, the remaining niche is appetite stimulation rather than superior GH-axis signaling.

the core tension

GHRP-2 isn't a bad compound. It does what it's supposed to do. Binds ghrelin receptors (GHSR), triggers pulsatile GH release, produces the downstream IGF-1 response that users are after. The problem is what else it does along the way: cortisol elevation (meaningful when cortisol management is already a concern, which for most GH-peptide users it is), prolactin elevation (relevant for sexual function and gynecomastia risk), and substantial appetite stimulation (useful if bulking, counterproductive if cutting). Ipamorelin (A-tier) does the same core job, pulsatile GH release via the same receptor, without any of those side effects. Same availability, same price, cleaner profile. The tier here reflects obsolescence, not failure.

what it is

ghrp-2 is a synthetic hexapeptide ghrelin receptor agonist originally developed by Cyril Bowers and colleagues at Tulane University in the early 1990s as candidate KP-102 / pralmorelin. Kaken Pharmaceutical took it through Japanese diagnostic registration. It binds GHSR in the pituitary and hypothalamus to trigger pulsatile growth hormone release. Half-life is 15-60 minutes, designed for multiple small daily injections.

what it does

ghrp-2 stimulates strong, reliable GH release, robust enough that it's used as a diagnostic provocation test for GH deficiency. Community use targets the downstream IGF-1 elevation for muscle building and recovery. The same receptor activation also elevates cortisol, prolactin, and appetite, none of which most chronic users want.

origin

investigated for GH deficiency and short stature through phase 2 in the 1990s and 2000s without achieving approval. Entered grey-market community use in the 2000s, then was largely displaced by ipamorelin in the 2010s as the cortisol and prolactin profile became widely understood. Still used clinically as a pituitary diagnostic provocation agent.

why researchers are interested

cheap, available, and pharmacologically real. The GH pulse is genuine. For users who want appetite stimulation during a bulk, the hunger spike is a feature rather than a bug. The diagnostic literature gives the compound a legitimate clinical anchor that newer research peptides don't have.

does it work

the GH release is well-established. The cortisol and prolactin elevation are equally well-established, documented by Arvat 2001 and Laferrere 2005. Ipamorelin binds the same receptor, produces the same pulsatile GH release, and carries a cleaner endocrine profile. The remaining GHRP-2 use case is appetite stimulation, not a superior GH signal.

claims vs the data

  • stimulates pulsatile GH release via GHSR agonism — supported — Core pharmacology, well-established across clinical and community use. The mechanism works as advertised.
  • produces significant cortisol and prolactin elevation — supported — Documented in multiple clinical studies. This is the distinguishing feature versus ipamorelin and the core of the tier placement.
  • stimulates appetite strongly — supported — Ghrelin receptor agonism inherently drives hunger, this is a pharmacological feature, not a bug. GHRP-2 produces it more than ipamorelin at equivalent doses.
  • useful for building muscle and accelerating recovery — partially true — The GH release is real. Whether the cortisol counterbalance blunts the anabolic signal depends on exposure pattern, concurrent compounds, and individual context. Community-level results are consistent with 'works, but ipamorelin works as well or better with fewer sides.'
  • equivalent to ipamorelin for most users — contradicted — Same target receptor, worse side effect profile. Not equivalent in any meaningful sense. The community progression from GHRP-2 to ipamorelin happened for a reason.

key facts

  • molecular formula: C45H55N9O6
  • molecular weight: 817.97 Da
  • amino acids: 6
  • half-life: approximately 15-60 minutes; short-acting pulsatile effect
  • type: hexapeptide, ghrelin receptor (GHSR) agonist
  • CAS: 158861-67-7
  • GHSR the ghrelin receptor it binds
  • cortisol + prolactin the distinguishing side effects vs ipamorelin
  • no FDA dose no approved chronic-use dosing framework
  • ipamorelin the cleaner alternative displacing it

frequently asked questions

What is GHRP-2?

GHRP-2 (Growth Hormone Releasing Peptide-2) is a synthetic hexapeptide that binds the ghrelin receptor to trigger pituitary growth hormone release. Developed in the 1980s-1990s as an oral GH secretagogue candidate that never reached approved drug status.

What does GHRP-2 do?

GHRP-2 stimulates strong, reliable GH release from the pituitary gland, the effect is well-documented enough that the compound is used as a diagnostic provocation test for GH deficiency. Community use targets the downstream IGF-1 elevation for muscle building and recovery, but the compound also meaningfully elevates cortisol and prolactin, which complicates chronic use.

How is GHRP-2 typically administered?

Clinical diagnostic use involves single-dose provocation testing in controlled settings. Community chronic-use patterns do not map to an FDA-approved dosing protocol, and the cortisol/prolactin baggage matters more in chronic exposure than in one-time endocrine testing.

What are the side effects of GHRP-2?

The distinguishing feature vs ipamorelin: GHRP-2 elevates cortisol, prolactin, and appetite alongside GH release. Common reports include injection-site reactions, increased hunger, occasional fluid retention, and for some users, mood effects from the cortisol/prolactin changes. For most chronic-use goals, ipamorelin produces similar GH effects without these tradeoffs.

Is GHRP-2 FDA approved?

No. GHRP-2 has no FDA approval as a therapeutic drug. It is used in some diagnostic contexts outside the US for pituitary function testing. WADA Prohibited List S2 applies for competitive athletes.

How much does GHRP-2 cost?

No clinical retail price. On the research-chemical market it is one of the cheaper GH secretagogues, though the side effect profile has driven most community users toward slightly-pricier ipamorelin.

related peptides

  • ipamorelin — the clean A-tier alternative that obsoleted it
  • cjc-1295 — the GHRH side of the GH stimulation equation
  • hgh — the endpoint hormone the secretagogues stimulate

reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.